Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| First quarter 2019 financial results | ||
| By: Nasdaq / GlobeNewswire - 25 Apr 2019 | Back to overview list |
|
Vistin Pharma ASA: First quarter 2019 financial results Oslo, Norway, 25 April 2019 Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the first quarter of 2019. The revenues for the first quarter 2019 ended at NOK 42.0 million (Q1 2018: NOK 52.6 million). The revenues were negatively impacted by the effect of the planned stop in production to install the new packaging line at Vistin Pharma’s metformin plant. The net profit ended at NOK 2.0 million (5.8) in the first quarter 2019, which included an unrealised gain on oil derivatives outstanding of NOK 6.4 million for the period. Vistin Pharma had cash of NOK 299.6 million as of 31 March 2019. The first quarter conference call, which will be held in Norwegian, will be available via web and audio through the following access points: Telephone conference: Webcast: Please find the report for the first quarter 2019 enclosed. The report will also be made available on www.vistin.com. ***** For further information, please contact: Kjell-Erik Nordby Gunnar Manum About Vistin Pharma | www.vistin.com Vistin Pharma is a Norwegian pharmaceutical company producing Metformin Hydrochloride (API). The Metformin is also available as Direct Compressible lubricated granules. As a solely dedicated European Metformin producer, Vistin Pharma is a well-positioned supplier to leading pharmaceutical companies. Vistin Pharma is headquartered in Oslo, Norway, and has highly qualified employees and a dedicated manufacturing facility in Kragerø. Attachments |
||
|
|
||
 | Back to overview list | |